Human Pathology
Volume 41, Issue 12 , Pages 1657-1663 , December 2010

Clinical and biological significance of GSK-3β inactivation in breast cancer—an immunohistochemical study

  • Hanan Armanious, MD, PhD

      Affiliations

    • Department of Laboratory Medicine and Pathology, Cross Cancer Institute and University of Alberta, Edmonton, Alberta, Canada T6G 1Z2
    • ,
  • Jean Deschenes, MD, FRCP

      Affiliations

    • Department of Laboratory Medicine and Pathology, Cross Cancer Institute and University of Alberta, Edmonton, Alberta, Canada T6G 1Z2
    • ,
  • Pascal Gelebart, PhD

      Affiliations

    • Department of Laboratory Medicine and Pathology, Cross Cancer Institute and University of Alberta, Edmonton, Alberta, Canada T6G 1Z2
    • ,
  • Sunita Ghosh, PhD

      Affiliations

    • Department of Biostatistics, Cross Cancer Institute and University of Alberta, Edmonton, Alberta, Canada T6G 1Z2
    • ,
  • John Mackey, MD, FRCP

      Affiliations

    • Department of Medicine, Cross Cancer Institute and University of Alberta, Edmonton, Alberta, Canada T6G 1Z2
    • ,
  • Raymond Lai, MD, PhD, FRCP

      Affiliations

    • Department of Laboratory Medicine and Pathology, Cross Cancer Institute and University of Alberta, Edmonton, Alberta, Canada T6G 1Z2
    • Corresponding Author InformationCorresponding author.

Received 15 January 2010 ,Revised 26 April 2010 ,Accepted 30 April 2010.

References 

  1. Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem. 1980;107:519–527
  2. Woodgett JR, Cohen P. Multisite phosphorylation of glycogen synthase. Molecular basis for the substrate specificity of glycogen synthase kinase-3 and casein kinase-II (glycogen synthase kinase-5). Biochim Biophys Acta. 1984;788:339–347
  3. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci. 2003;116(Pt 7):1175–1186
  4. Shakoori A, Ougolkov A, Yu ZW, et al. Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun. 2005;334:1365–1373
  5. Cao Q, Lu X, Feng YJ. Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res. 2006;16:671–677
  6. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, et al. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res. 2005;65:2076–2081
  7. Cohen P, Alessi DR, Cross DA. PDK1, one of the missing links in insulin signal transduction?. FEBS Lett. 1997;410:3–10
  8. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem. 1998;273:19929–19932
  9. Miller JR. The Wnts. Genome Biol. 2002;3:REVIEWS3001
  10. Mikels AJ, Nusse R. Wnts as ligands: processing, secretion and reception. Oncogene. 2006;25:7461–7468
  11. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem. 2006;281:22429–22433
  12. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127:469–480
  13. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci. 2004;29:95–102
  14. Sanchez JF, Sniderhan LF, Williamson AL, et al. Glycogen synthase kinase 3beta-mediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor kappaB signaling. Mol Cell Biol. 2003;23:4649–4662
  15. Bose S, Chandran S, Mirocha JM, et al. The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol. 2006;19:238–245
  16. Tokunaga E, Kimura Y, Mashino K, et al. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer. 2006;13:137–144
  17. Ding Q, He X, Xia W, et al. Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res. 2007;67:4564–4571
  18. Chung R, Peters AC, Armanious H, et al. Biological and clinical significance of GSK-3beta in mantle cell lymphoma—an immunohistochemical study. Int J Clin Exp Pathol. 2010;25(3):244–253
  19. Gelebart P, Anand M, Armanious H, et al. Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. Blood. 2008;112:5171–5179
  20. Yaziji H, Taylor CR, Goldstein NS, et al. Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol. 2008;16:513–520
  21. Wolff AC, Hammond ME, Schwartz JN, Wheeler TM, Hayes DF, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–145
  22. Hagen T, Di Daniel E, Culbert AA, et al. Expression and characterization of GSK-3 mutants and their effect on beta-catenin phosphorylation in intact cells. J Biol Chem. 2002;277:23330–23335
  23. Fang X, Yu SX, Lu Y, et al. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A. 2000;97:11960–11965
  24. Stambolic V, Woodgett JR. Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem J. 1994;303(Pt 3):701–704
  25. Chung GG, Zerkowski MP, Ocal IT, et al. beta-Catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer. 2004;100:2084–2092
  26. Lin SY, Xia W, Wang JC, et al. beta-Catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A. 2000;97:4262–4266
  27. Ryo A, Nakamura M, Wulf G, et al. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol. 2001;3:793–801
  28. Fang D, Hawke D, Zheng Y, et al. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem. 2007;282:11221–11229
  29. Elsheikh S, Green AR, Aleskandarany MA, et al. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat. 2008;109:325–335
  30. Diehl JA, Cheng M, Roussel MF, et al. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998;12:3499–3511
  31. Yang K, Guo Y, Stacey WC, et al. Glycogen synthase kinase 3 has a limited role in cell cycle regulation of cyclin D1 levels. BMC Cell Biol. 2006;7:33
  32. Ougolkov AV, Billadeau DD. Targeting GSK-3: a promising approach for cancer therapy?. Future Oncol. 2006;2:91–100
  33. Panigrahi AR, Pinder SE, Chan SY, et al. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol. 2004;204:93–100
  34. Schmitz KJ, Otterbach F, Callies R, et al. Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol. 2004;17:15–21

PII: S0046-8177(10)00165-6

doi: 10.1016/j.humpath.2010.04.015

Human Pathology
Volume 41, Issue 12 , Pages 1657-1663 , December 2010

Article Tools

* Image Usage & Resolution